disease

Glaucoma

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about Glaucoma: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

1047Connections

0Hypotheses

0Analyses

50Outgoing

50Incoming

No summary available yet. View on Wiki →

Disease Info

Prevalence	~80 million people worldwide
Age	Glaucoma prevalence increases exponentially with age, reflecting cumulative damage and reduced regenerative capacity.
Genetics	Family history increases risk 4-10 fold. Multiple susceptibility loci have been identified (MYOC, OPTN, WDR36, CAV1/CAV2).
Ethnicity	African and Hispanic populations have higher prevalence and earlier onset.
Central Corneal Thickness	Thinner corneas are associated with higher glaucoma risk.
Topical Medications	Prostaglandin analogs (latanoprost, bimatoprost), beta-blockers, alpha-agonists, carbonic anhydrase inhibitors
Laser Therapy	Selective laser trabeculoplasty (SLT)
Surgical	Trabeculectomy, tube shunts, MIGS (minimally invasive glaucoma surgery)
Associated Genes	NLRP3, CD8, OVERVIEW, STING, STING1, Caspase-3, COMPLEMENT, MICROGLIA
Therapeutic Agents	NADPH, NAC, Nadph, Nac, Indoleacetic Acid
KG Connections	508 knowledge graph edges
Databases	OMIM Orphanet ClinicalTrials PubMed

Wiki Pages (21)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    Glaucoma["<b>Glaucoma</b>"]
    Complement__Inflammasome__and_["Complement, Inflammasome, and Microglial Crosstalk"]
    Glaucoma -->|"associated_with"| Complement__Inflammasome__and_
    Amyotrophic_Lateral_Sclerosis{"Amyotrophic Lateral Sclerosis"}
    Glaucoma -->|"associated_with"| Amyotrophic_Lateral_Sclerosis
    Tryptophan_Metabolism["Tryptophan Metabolism"]
    Glaucoma -->|"associated_with"| Tryptophan_Metabolism
    AHR["AHR"]
    Glaucoma -->|"associated_with"| AHR
    MAPK["MAPK"]
    Glaucoma -->|"associated_with"| MAPK
    Autophagy["Autophagy"]
    Glaucoma -->|"therapeutic_target"| Autophagy
    AMYOTROPHIC_LATERAL_SCLEROSIS(["AMYOTROPHIC LATERAL SCLEROSIS"])
    AMYOTROPHIC_LATERAL_SCLEROSIS -->|"associated_with"| Glaucoma
    NEURODEGENERATION(["NEURODEGENERATION"])
    NEURODEGENERATION -->|"associated_with"| Glaucoma
    OPTN(["OPTN"])
    OPTN -->|"associated_with"| Glaucoma
    AHR_RAGE_Pathway["AHR/RAGE Pathway"]
    AHR_RAGE_Pathway -->|"involved_in"| Glaucoma
    style Glaucoma fill:#1a3a4a,stroke:#ef5350,stroke-width:3px,color:#e0e0e0

Outgoing (494)

Target	Relation	Type	Str
Complement, Inflammasome, and Microglial Crosstalk	associated_with	mechanism	0.95
Retinal Ganglion Cell Degeneration	causes	process	0.95
Vision Loss	causes	phenotype	0.95
Retinal Ganglion Cell	associated_with	cell_type	0.95
Retinal Ganglion Cell Loss	causes	phenotype	0.95
Optic Nerve Degeneration	causes	phenotype	0.95
Retinal Ganglion Cell Death	causes	process	0.95
Amyotrophic Lateral Sclerosis	associated_with	disease	0.85
Tryptophan Metabolism	associated_with	pathway	0.80
MAPK	associated_with	pathway	0.70
Autophagy	therapeutic_target	pathway	0.70
Neurodegeneration	inhibits	disease	0.65
Neurodegeneration	biomarker_for	disease	0.65
Neurodegeneration	associated_with	disease	0.65
Immune Response	associated_with	pathway	0.60
Dysbiosis	associated_with	pathway	0.60
Microbiota	regulates	pathway	0.60
Nf-Κb	inhibits	pathway	0.60
Autophagy	biomarker_for	pathway	0.60
Mitophagy	biomarker_for	pathway	0.60
Apoptosis	biomarker_for	pathway	0.60
Oxidative Stress	therapeutic_target	pathway	0.60
Apoptosis	therapeutic_target	pathway	0.60
Senescence	therapeutic_target	pathway	0.60
Immune Response	activates	pathway	0.60
Autophagy	regulates	pathway	0.60
Nf-Κb	regulates	pathway	0.60
Interferon Signaling	regulates	pathway	0.60
Autophagy	implicated_in	pathway	0.60
Immunotherapy	implicated_in	pathway	0.60
Immune Response	implicated_in	pathway	0.60
Autophagy	activates	pathway	0.60
Nf-Κb	activates	pathway	0.60
Stem Cell	regulates	pathway	0.60
Stem Cell	activates	pathway	0.60
Oxidative Stress	causes	pathway	0.60
Autophagy	causes	pathway	0.60
Apoptosis	causes	pathway	0.60
Stem Cell	causes	pathway	0.60
Lysosomal Degradation	associated_with	pathway	0.60
Autophagy	associated_with	pathway	0.60
Mtor	associated_with	pathway	0.60
Stem Cell	associated_with	pathway	0.60
Apoptosis	activates	pathway	0.60
Complement	therapeutic_target	pathway	0.55
Inflammasome	therapeutic_target	pathway	0.55
Inflammasome	associated_with	pathway	0.55
Complement	associated_with	pathway	0.55
Senescence	activates	pathway	0.55
Neuroinflammatory	inhibits	pathway	0.55

Incoming (553)

Source	Relation	Type	Str
AMYOTROPHIC LATERAL SCLEROSIS	associated_with	gene	1.00
NEURODEGENERATION	associated_with	gene	0.95
OPTN	associated_with	gene	0.95
Retinal Ganglion Cell Loss	causes	process	0.95
Elevated Intraocular Pressure	risk_factor_for	phenotype	0.95
Microbiota	contributes_to	process	0.95
Redox Imbalance	contributes_to	process	0.95
AHR/RAGE Pathway	involved_in	pathway	0.90
Intraocular Pressure	risk_factor_for	biomarker	0.90
Neurodegeneration	involved_in	process	0.90
NLRP3 INFLAMMASOME	involved_in	protein	0.90
Neuroinflammation	involved_in	process	0.90
Gut Microbiota	protects_against	process	0.90
Complement-Nlrp3-Microglia Axis	causes	pathway	0.90
Lps-Tlr4 Pathway	involved_in	pathway	0.90
astrocyte network	therapeutic_target	cell_type	0.90
ocular hypertension	risk_factor_for	phenotype	0.90
Complement	contributes_to	pathway	0.90
Tryptophan Metabolites	protects_against	compound	0.88
Perivascular Niche	protects_against	process	0.88
Indoleacetic Acid	treats	compound	0.88
Aging	risk_factor_for	process	0.88
Retinal Ganglion Cell Loss	biomarker_for	phenotype	0.85
NEURODEGENERATIVE DISEASES	associated_with	gene	0.85
Genetics	risk_factor_for	process	0.85
Age	risk_factor_for	biomarker	0.85
Neuroprotection	protects_against	process	0.85
AHR/RAGE Pathway	protects_against	pathway	0.85
Gut Microbiota	associated_with	process	0.85
C1Q	involved_in	protein	0.85
C3	involved_in	protein	0.85
C5	involved_in	protein	0.85
Indoleacetic Acid	therapeutic_target	compound	0.85
NLRP3	involved_in	protein	0.85
Tryptophan Metabolism	involved_in	process	0.80
Intraocular Pressure Lowering	treats	process	0.80
Complement	associated_with	pathway	0.80
NLRP3 Inflammasome	associated_with	pathway	0.80
Microglia	associated_with	cell_type	0.80
C1q	upregulates	protein	0.80
C3	upregulates	protein	0.80
C5	upregulates	protein	0.80
NLRP3	activates	protein	0.80
Serum Indoleacetic Acid	biomarker_for	biomarker	0.80
Direction-Selective Rgc	protects_against	cell_type	0.80
M1 Iprgc	protects_against	cell_type	0.80
PIEZO1	involved_in	protein	0.80
Obesity	contributes_to	phenotype	0.80
Depression	contributes_to	disease	0.80
Piezo1	implicated_in	protein	0.80

Targeting Hypotheses (0)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
No targeting hypotheses

Mentioning Analyses (0)

Scientific analyses that reference this entity

No analyses mention this entity

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Glaucoma

Understanding Entity Pages

Wiki Pages (21)

retinal-ganglion-cells-glaucoma

cbs-psp-daily-action-plan

Section 162: Advanced Antioxidant and Redox Therapy in CBS/PSP

Neuroprotection Strategies in Neurodegeneration

Gene-Mechanism-Therapy Causal Chains

KarXT for Alzheimer's Disease Cognitive Impairment - MINDSET 2 (NCT06976203)

Section 233: Advanced Virtual Reality and Immersive Technology-Based Rehabilitation in CBS/PSP

NF-kB Signaling Pathway in Neurodegeneration

Mitophagy Pathway in Neurodegeneration

KarXT+EC Phase 3 (NCT07011732): Enhanced Formulation for AD Agitation

ROCK1 Gene

FGF Signaling Pathway in Neurodegeneration

lmx1b

Complement-Mediated Synapse Loss

Kinesin-1 Heavy Chain Protein

EPG5 Gene - Ectopic P-Granules 5 Autophagy Tutor

LY03020 - Luye Pharma Phase 1 Trial

Retinal Biomarkers in Neurodegeneration

Diseases